

Clinical characteristics and outcome of multiple myeloma patients with concomitant COVID-19 at Comprehensive Cancer Centers in Germany

Monika Engelhardt,^{1,2} Khalid Shoumariyeh,^{1,2} Amelie Rösner,¹ Gabriele Ihorst,³ Francesca Biavasco,^{1,2} Katharina Meckel,⁴ Ivana von Metzler,⁵ Sebastian Theurich,⁶ Holger Hebart,⁷ Matthias Grube,⁸ Miriam Kull,⁹ Florian Bassermann,¹⁰ Kerstin Schäfer-Eckart,¹¹ Anette Hoferer,¹² Hermann Einsele,⁴ Leo Rasche⁴ and Ralph Wäsch^{1,2}

¹Freiburg University Medical Center, Department of Internal Medicine I, Faculty of Medicine, University of Freiburg, Freiburg; ²German Cancer Consortium (DKTK) Heidelberg, Heidelberg; ³Clinical Trials Unit Freiburg, Faculty of Medicine, University of Freiburg, Freiburg; ⁴Medizinische Klinik und Poliklinik II, Julius-Maximilian-University of Würzburg, Würzburg; ⁵Universitätsklinik Frankfurt, Department of Hematology and Oncology, University of Frankfurt, Frankfurt; ⁶LMU University Hospital München, Department of Internal Medicine III, Ludwig-Maximilian-University München, München; ⁷Kliniken Ostalb, Stauferklinikum, Muttlangen; ⁸Universitätsklinik Regensburg, Department of Hematology and Oncology, University of Regensburg, Regensburg; ⁹Universitätsklinik Ulm, Department of Hematology and Oncology, University of Ulm, Ulm; ¹⁰Florian Bassermann Klinikum rechts der Isar, Department of Hematology and Oncology, München; ¹¹Klinikum Nürnberg, Department of Hematology and Oncology, Nürnberg and ¹²Robert-Bosch Krankenhaus, Stuttgart, Germany

Correspondence: MONIKA ENGELHARDT - monika.engelhardt@uniklinik-freiburg.de

doi:10.3324/haematol.2020.262758

Supplementary Table 1. Patients in need of ICU support vs. without

Parameters	ICU support (n=3)	No ICU support (n=18)
<i>Patient characteristics</i>		
Median age (years; range)	60 (56-62)	58 (46-83)
Male : female	3 : 0	14 : 4
Median Karnofsky Performance Status (%; range)	60 (30-70)	90 (60-100)
Median number of comorbidities (range)	2 (1-3)	1 (0-2)
Smoking : non-smoking	1 : 2	3 : 15
Median R-MCI (range)	6 (4-7)	3 (0-7)
Median IMWG-frailty score (range)	2 (1-3)	1 (0-2)
<i>MM disease characteristics</i>		
Cytogenetic risk: HR : SR	1 : 2	5 : 13
Median # of CRAB criteria	3	2
MM disease status @ Covid-19 infection		
ID	1	1
CR	1	5
VGPR / PR	1	3 / 9
Number of prior anti-MM lines	1	1
Prior transplant: yes : no	1 : 2	14 : 4
Anti-MM treatment @ Covid-19		
Daratumumab-combination	1	3
Elotuzumab-combination		1
VCd / KRd		2 / 1
R-maintenance		3
no MM therapy	2	7
<i>Covid-19 disease outcome parameters</i>		
Median time of Covid-19 infection since MM ID (ms)	2	22
Time from symptoms to test (days)	5	3
Median laboratory parameters		
ANC (x10 ⁹ /L)	2.8	3.0
ALC (x10 ⁹ /L)	0.5	0.9
LDH (U/l)	532	200
CRP (mg/l)	245	50
Ferritin (µg/l)	5000	46
Creatinine clearance (ml/min)	21	79
Median time to recovery (days)		
from symptom onset	61	16
from test positivity	52	14
Inpatient : outpatient treatment: yes : no	3 : 0	14 : 4
Median time of inpatient treatment (days)	52	14
Alive status (%)	100%	100%
Covid-19 treatment		
po antibiotics / iv antibiotics	0 / 3	2 : 12
plus Azithromycin	1	3
Hydroxychloroquin	2	5
Remdesivir	1	0
Tocilizumab	1	0
Anakinra	0	1
Supportives only	0	4

Abbreviations:

R-MCI: revised myeloma comorbidity index, IMWG: International Myeloma Working Group-frailty index

HR: high risk: del17p, t(4;14), t(14;16); SR: all others,

CRAB: hypercalcemia, anemia, renal impairment, bone disease,

ID: initial diagnosis of MM, CR: complete response, VGPR/PR: very good partial response/partial response,

transplant: ASCT, VCd / KRd: bortezomib-cyclophosphamid-dexamethasone / carfilzomib-lenalidomide-dexamethasone, R: lenalidomide, ms: months